2018, Compounding and Controlled Substances

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2018

Compounding

Controlled Substances

How API CMOs can improve containment capabilities without facility acquisition

Pharmaceutical Technology

NOVEMBER 17, 2022

According to GlobalData analysis, specialist small molecule API capabilities such as containment or controlled substances are driving large contract manufacturing organisations (CMOs) to acquire facilities. However, site selection and facility acquisition can be a challenge, as well as being a major capital expenditure (CAPEX).

Controlled Substances

Controlled Substances Compounding

DEA’s Expected Guidance: It Should Reduce Current “Pain” at the (Intrathecal Pain) Pump Dispensing Process and Improve Therapeutic Outcomes

FDA Law Blog: Biosimilars

JUNE 23, 2024

Palmer — For more than 50 years, the Drug Enforcement Administration (DEA) has enforced the central mandate of the Controlled Substances Act (CSA) to maintain a closed chain of distribution for drugs with a potential for abuse and diversion. 2] Why is this an issue? However, two events conspired to undermine this prior guidance.

Controlled Substances

Controlled Substances Compounding

Webinars

Best Practices to Streamline Compensation Management: A Foundation for Growth

MORE WEBINARS

Pharmacist Digest

How API CMOs can improve containment capabilities without facility acquisition

DEA’s Expected Guidance: It Should Reduce Current “Pain” at the (Intrathecal Pain) Pump Dispensing Process and Improve Therapeutic Outcomes

Webinars

Stay Connected